These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36412034)

  • 1. [A Case of Breast Cancer Recurrence Responding to Trastuzumab Deruxtecan for Increased Cervical Lymph Node Metastasis during Anti-HER2 Therapy].
    Yamaguchi Y; Yamashiro Y; Tamura S; Hirooka K
    Gan To Kagaku Ryoho; 2022 Nov; 49(11):1267-1269. PubMed ID: 36412034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A Case of Bilateral HER2-Positive Invasive Ductal Carcinoma with Complete Response on One Side with Trastuzumab Deruxtecan].
    Miyazaki S; Iwasaki K; Narita T; Yoneda G; Takei H; Jibiki N
    Gan To Kagaku Ryoho; 2023 Mar; 50(3):327-331. PubMed ID: 36927901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
    Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
    Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B
    J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
    Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
    World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
    Bartsch R
    Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
    Mukohara T; Hosono A; Mimaki S; Nakayama A; Kusuhara S; Funasaka C; Nakao T; Fukasawa Y; Kondoh C; Harano K; Naito Y; Matsubara N; Tsuchihara K; Kuwata T
    Oncologist; 2021 Aug; 26(8):635-639. PubMed ID: 33559918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
    Nakajima H; Harano K; Nakai T; Kusuhara S; Nakao T; Funasaka C; Kondoh C; Matsubara N; Naito Y; Hosono A; Mitsunaga S; Ishii G; Mukohara T
    Breast; 2022 Feb; 61():136-144. PubMed ID: 34999427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer.
    Nur Husna SM; Wong KK
    Mol Immunol; 2022 Dec; 152():45-54. PubMed ID: 36272249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
    Modi S
    Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
    Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A Case in Which Re-Administration of Pertuzumab/Trastuzumab with Eribulin Therapy Was Useful for Recurrent HER2 Breast Cancer].
    Kouhashi R; Kashiwagi S; Kawano Y; Yabumoto A; Ishihara S; Goto W; Asano Y; Tauchi Y; Morisaki T; Noda S; Takashima T; Hirakawa K; Ohira M
    Gan To Kagaku Ryoho; 2020 Dec; 47(13):2230-2232. PubMed ID: 33468917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
    Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F
    Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How we treat patients with metastatic HER2-positive breast cancer.
    Nader-Marta G; Martins-Branco D; de Azambuja E
    ESMO Open; 2022 Feb; 7(1):100343. PubMed ID: 34995893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.
    Li JW; Mo M; Yu KD; Chen CM; Hu Z; Hou YF; Di GH; Wu J; Shen ZZ; Shao ZM; Liu GY
    PLoS One; 2014; 9(12):e114646. PubMed ID: 25504233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
    Van Raemdonck E; Floris G; Berteloot P; Laenen A; Vergote I; Wildiers H; Punie K; Neven P
    Breast Cancer Res Treat; 2021 Jan; 185(1):183-194. PubMed ID: 32980945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xeloda Oral, Trastuzumab, and Pertuzumab Combined Drug Therapy Reduced Cervical Lymphadenopathy and Dermal Involvement in Patient With Recurrent Breast Cancer: Case Report.
    Saure Sarría VM; Arencibia AD; D'Afonseca V
    J Investig Med High Impact Case Rep; 2020; 8():2324709620942606. PubMed ID: 32720808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: a case report.
    Takahashi M; Inoue K; Goto R; Tamura M; Taguchi K; Takahashi H; Suzuki H; Katsushige K; Ogita M
    Breast Cancer; 2003; 10(2):170-4. PubMed ID: 12736573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.